Sanj K. Patel's most recent trade in Relay Therapeutics Inc was a trade of 42,740 Common Stock done at an average price of $3.6 . Disclosure was reported to the exchange on July 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.57 per share. | 09 Jul 2025 | 42,740 | 783,927 | - | 3.6 | 152,582 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.57 per share. | 09 Jul 2025 | 18,639 | 765,288 | - | 3.6 | 66,541 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.94 per share. | 30 Jun 2025 | 5,000 | 826,667 | - | 2.9 | 14,700 | Common Stock |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 23 May 2025 | 62,116 | 158,790 (0%) | 0% | 1.6 | 98,764 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.33 per share. | 23 May 2025 | 62,116 | 96,674 (0%) | 0% | 27.3 | 1,697,630 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2025 | 62,116 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 23 May 2025 | 19,317 | 115,991 (0%) | 0% | 1.6 | 30,714 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 23 May 2025 | 19,317 | 96,674 (0%) | 0% | 27.0 | 521,752 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2025 | 19,317 | 62,116 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 23 May 2025 | 4,837 | 101,511 (0%) | 0% | 1.6 | 7,691 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 23 May 2025 | 4,837 | 96,674 (0%) | 0% | 27 | 130,599 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2025 | 4,837 | 81,433 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2025 | 2,349 | 86,270 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 20 May 2025 | 2,349 | 99,023 (0%) | 0% | 1.6 | 3,735 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.02 per share. | 20 May 2025 | 2,349 | 96,674 (0%) | 0% | 27.0 | 63,470 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 13 May 2025 | 2,872 | 99,546 (0%) | 0% | 1.6 | 4,566 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 2,872 | 88,619 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.03 per share. | 13 May 2025 | 2,872 | 96,674 (0%) | 0% | 27.0 | 77,630 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.05 per share. | 07 May 2025 | 6,029 | 96,674 (0%) | 0% | 27.0 | 163,084 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 07 May 2025 | 6,029 | 102,703 (0%) | 0% | 1.6 | 9,586 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 6,029 | 91,491 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 07 May 2025 | 1,965 | 96,674 (0%) | 0% | 27 | 53,055 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 07 May 2025 | 1,965 | 98,639 (0%) | 0% | 1.6 | 3,124 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 1,965 | 97,621 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 07 May 2025 | 101 | 96,674 (0%) | 0% | 27 | 2,727 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 07 May 2025 | 101 | 96,775 (0%) | 0% | 1.6 | 161 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 101 | 97,520 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 13,328 | 26,238 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 12,910 | 12,910 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 8,386 | 8,386 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 7,987 | 7,987 | - | - | Performance Share Unit | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.97 per share. | 23 Apr 2025 | 42,769 | 840,320 | - | 3.0 | 127,024 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.97 per share. | 23 Apr 2025 | 18,653 | 821,667 | - | 3.0 | 55,399 | Common Stock |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 9,992 | 101,506 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 9,992 | 9,991 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 07 Apr 2025 | 4,832 | 96,674 (0%) | 0% | 20.3 | 97,993 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 137,638 | 137,638 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 68,869 | 68,869 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 34,435 | 34,435 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 6,481 | 90,597 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 6,481 | 12,962 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 6,238 | 96,835 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 6,238 | 18,712 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 3,017 | 91,514 (0%) | 0% | 21.8 | 65,680 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 2,304 | 94,531 (0%) | 0% | 21.8 | 50,158 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 6,569 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 6,569 | 86,120 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.61 per share. | 16 Mar 2025 | 2,004 | 84,116 (0%) | 0% | 22.6 | 45,310 | Class A Ordinary Share |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 332,465 | 958,413 | - | 0 | Common Stock | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.85 per share. | 11 Feb 2025 | 140,182 | 625,948 | - | 3.9 | 539,701 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.70 per share. | 11 Feb 2025 | 75,324 | 883,089 | - | 3.7 | 278,699 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.78 per share. | 21 Jan 2025 | 125,000 | 199,548 | - | 4.8 | 597,500 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.52 per share. | 21 Jan 2025 | 125,000 | 449,548 | - | 4.5 | 565,000 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 21 Jan 2025 | 125,000 | 324,548 | - | 4.8 | 600,000 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 1,105,000 | 1,105,000 | - | - | Stock Option (Right to Buy) | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 16 Dec 2024 | 100,000 | 574,548 | - | 5 | 500,000 | Common Stock |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 06 Nov 2024 | 89,561 | 79,551 (0%) | 0% | 23 | 2,059,903 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 89,561 | 10,025 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 06 Nov 2024 | 89,561 | 169,112 (0%) | 0% | 1.6 | 142,402 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 129,750 | 129,750 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 24,950 | 24,950 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 16,474 | 84,126 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 9,992 | 19,983 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 01 Sep 2024 | 7,967 | 76,159 (0%) | 0% | 26.7 | 213,038 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 6,569 | 82,728 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 6,569 | 6,569 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 6,482 | 19,443 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 01 Sep 2024 | 3,177 | 79,551 (0%) | 0% | 26.7 | 84,953 | Class A Ordinary Share |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.04 per share. | 25 Jul 2024 | 50,000 | 816,130 | - | 5.0 | 252,000 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2024 | 50,000 | 518,779 | - | - | Stock Option (Right to Buy) | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.16 per share. | 25 Jul 2024 | 50,000 | 766,130 | - | 9.2 | 458,000 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2024 | 36,706 | 482,073 | - | - | Stock Option (Right to Buy) | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.07 per share. | 25 Jul 2024 | 36,706 | 766,130 | - | 9.1 | 332,923 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.04 per share. | 25 Jul 2024 | 36,706 | 802,836 | - | 5.0 | 184,998 | Common Stock |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 23 Jul 2024 | 136,124 | 199,136 (0%) | 0% | 1.6 | 216,437 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jul 2024 | 136,124 | 189,147 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 23 Jul 2024 | 63,049 | 63,012 (0%) | 0% | 27.0 | 1,702,953 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 25.05 per share. | 23 Jul 2024 | 50,000 | 126,061 (0%) | 0% | 25.1 | 1,252,500 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 23 Jul 2024 | 23,075 | 176,061 (0%) | 0% | 23.3 | 536,494 | Class A Ordinary Share |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 5.54 per share. | 30 Jun 2024 | 2,108 | 766,130 | - | 5.5 | 11,678 | Common Stock |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 129,750 | 129,750 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 24,950 | 44,393 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 20,000 | 20,000 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 9,992 | 67,087 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 9,992 | 34,401 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.90 per share. | 04 Apr 2024 | 4,075 | 63,012 (0%) | 0% | 17.9 | 72,943 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 6,482 | 19,443 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 6,482 | 58,998 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.70 per share. | 01 Apr 2024 | 1,903 | 57,095 (0%) | 0% | 19.7 | 37,489 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 21.02 per share. | 07 Mar 2024 | 65,012 | 0 (0%) | 0% | 21.0 | 1,366,552 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 21.31 per share. | 04 Mar 2024 | 9,406 | 73,930 (0%) | 0% | 21.3 | 200,442 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 04 Mar 2024 | 5,582 | 65,012 (0%) | 0% | 21 | 117,222 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 04 Mar 2024 | 3,336 | 70,594 (0%) | 0% | 22 | 73,392 | Class A Common Share |
| Relay Therapeutics Inc | Patel Sanjiv K. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 762,360 | 764,022 | - | 0 | Common Stock | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 9,992 | 29,975 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 9,992 | 45,507 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.71 per share. | 10 Apr 2023 | 2,933 | 42,574 (0%) | 0% | 10.7 | 31,412 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 155,500 | 155,500 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 25,925 | 25,925 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 12,002 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 12,002 | 39,038 (0%) | 0% | - | Class A Common Share |